(0.26%) 5 145.00 points
(0.27%) 38 545 points
(0.37%) 17 912 points
(-0.80%) $83.18
(1.35%) $1.949
(-0.17%) $2 343.20
(1.13%) $27.56
(0.66%) $928.20
(-0.26%) $0.932
(-0.25%) $11.00
(-0.36%) $0.797
(0.87%) $92.68
0.45% INR 100.75
Live Chart Being Loaded With Signals
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives...
Stats | |
---|---|
Tagesvolumen | 7 592.00 |
Durchschnittsvolumen | 42 893.00 |
Marktkapitalisierung | 1.59B |
EPS | INR0 ( 2024-02-11 ) |
Nächstes Ertragsdatum | ( INR0 ) 2024-05-27 |
Last Dividend | INR1.000 ( 2023-09-18 ) |
Next Dividend | INR0 ( N/A ) |
P/E | 45.59 |
ATR14 | INR0.252 (0.25%) |
Volumen Korrelation
Bal Pharma Limited Korrelation
10 Am meisten positiv korreliert | |
---|---|
EMIL.NS | 0.925 |
INDIGOPNTS.NS | 0.921 |
MEDICAMEQ.NS | 0.921 |
GOCOLORS.NS | 0.92 |
NAVNETEDUL.NS | 0.919 |
SABEVENTS.NS | 0.916 |
ASAHISONG.NS | 0.915 |
MCLEODRUSS.NS | 0.912 |
SGL.NS | 0.91 |
IGPL.NS | 0.91 |
10 Am meisten negativ korreliert | |
---|---|
RAJRILTD.NS | -0.92 |
4THDIM.NS | -0.915 |
LTGILTBEES.NS | -0.898 |
ISMTLTD.NS | -0.889 |
GNA.NS | -0.865 |
KAYNES.NS | -0.865 |
JINDCOT.NS | -0.858 |
KIRLFER.NS | -0.852 |
SYMPHONY.NS | -0.85 |
SHRIRAMEPC.NS | -0.846 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Bal Pharma Limited Korrelation - Währung/Rohstoff
Bal Pharma Limited Finanzdaten
Annual | 2022 |
Umsatz: | INR3.04B |
Bruttogewinn: | INR1.31B (43.21 %) |
EPS: | INR1.640 |
FY | 2022 |
Umsatz: | INR3.04B |
Bruttogewinn: | INR1.31B (43.21 %) |
EPS: | INR1.640 |
FY | 2022 |
Umsatz: | INR2.81B |
Bruttogewinn: | INR1.11B (39.64 %) |
EPS: | INR3.79 |
FY | 2021 |
Umsatz: | INR2.51B |
Bruttogewinn: | INR993.03M (39.64 %) |
EPS: | INR3.34 |
Financial Reports:
No articles found.
Bal Pharma Limited Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR1.000 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
INR0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | INR0.750 | 2006-09-07 |
Last Dividend | INR1.000 | 2023-09-18 |
Next Dividend | INR0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 14 | -- |
Total Paid Out | INR13.00 | -- |
Avg. Dividend % Per Year | 0.69% | -- |
Score | 1.51 | -- |
Div. Sustainability Score | 1.444 | |
Div.Growth Potential Score | 2.52 | |
Div. Directional Score | 1.982 | -- |
Year | Amount | Yield |
---|---|---|
2006 | INR0 | 0.00% |
2007 | INR0 | 0.00% |
2008 | INR0 | 0.00% |
2009 | INR0 | 0.00% |
2010 | INR0 | 0.00% |
2011 | INR0 | 0.00% |
2012 | INR0 | 0.00% |
2013 | INR0 | 0.00% |
2014 | INR0 | 0.00% |
2015 | INR0 | 0.00% |
2016 | INR0 | 0.00% |
2017 | INR0 | 0.00% |
2018 | INR1.000 | 1.18% |
2019 | INR1.000 | 1.27% |
2020 | INR0 | 0.00% |
2021 | INR1.000 | 1.78% |
2022 | INR1.000 | 0.79% |
2023 | INR1.000 | 1.09% |
2024 | INR0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
RITES.NS | Dividend Knight | 2023-09-08 | Quarterly | 7 | 3.95% | |
LAMBODHARA.NS | Dividend Junior | 2023-09-14 | Annually | 10 | 0.87% | |
FORCEMOT.NS | Dividend Junior | 2023-09-21 | Annually | 6 | 0.45% | |
APLAPOLLO.NS | Ex Dividend Junior | 2023-09-01 | Sporadic | 13 | 0.07% | |
TATVA.NS | Dividend Junior | 2023-09-08 | Annually | 3 | 0.04% | |
NUCLEUS.NS | Dividend Junior | 2023-07-07 | Annually | 22 | 1.41% | |
INDUSINDBK.NS | Dividend Junior | 2023-06-02 | Annually | 23 | 0.56% | |
COLPAL.NS | Dividend Knight | 2023-05-19 | Semi-Annually | 18 | 1.38% | |
SBIN.NS | Dividend Junior | 2023-05-31 | Sporadic | 29 | 0.99% | |
MAHSEAMLES.NS | Dividend Junior | 2023-08-14 | Annually | 21 | 0.80% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0142 | 1.500 | 9.72 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0 | 1.200 | 0 | 0 | [0 - 0.3] |
returnOnEquityTTM | 0.0729 | 1.500 | -0.301 | -0.451 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 0 | 0.800 | -5.00 | -4.00 | [1 - 3] |
quickRatioTTM | 0 | 0.800 | -4.71 | -3.76 | [0.8 - 2.5] |
cashRatioTTM | 0 | 1.500 | -1.111 | -1.667 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 1.455 | 1.000 | -0.572 | -0.572 | [3 - 30] |
operatingCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 12.66 | 2.00 | 3.67 | 7.34 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0.440 | 1.000 | 6.00 | 6.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0666 | 1.000 | -0.667 | -0.667 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | 1.444 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.24 | 1.000 | 6.64 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0729 | 2.50 | -0.193 | -0.451 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 7.34 | [0 - 30] |
dividendYielPercentageTTM | 0.997 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 12.66 | 2.00 | 5.78 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.604 | 1.500 | -7.36 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0612 | 1.000 | -0.970 | 0 | [0.1 - 0.5] |
Total Score | 2.52 |
Bal Pharma Limited
Bal Pharma Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk actives. It provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostrate enlargement, renal calculi, male infertility, women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands. The company also offers a range of APIs for therapeutic areas, such as anti-histamine, platelet inhibitor, anti-diabetic, anti convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, etc.; and various formulations. In addition, it engages in the treatment of gastrointestinal disorders; and piles, fistula, and constipation. The company exports its products to Europe, Latin America, Africa, the Far East, the Middle East, and internationally. Bal Pharma Limited was incorporated in 1987 and is based in Bengaluru, India.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.